Funder
U.S. Food and Drug Administration
NIH National Center for Advancing Translational Sciences
Publisher
Springer Science and Business Media LLC
Subject
Anesthesiology and Pain Medicine,Neurology (clinical)
Reference59 articles.
1. Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182–6.
2. Dart MD, PhD RC, Iwanicki MDJL, Dasgupta PhDN, Cicero PhDTJ, Schnoll MD, PhD SH. Do abuse deterrent opioid formulations work? J Opioid Manag. 2017;13(6):365.
3. Rauck RL. Mitigation of abuse through the use of abuse-deterrent opioid formulations: an overview of current technologies. Pain Pract. 2019;19(4):443–54.
4. US Food and Drug Administration. Abuse-Deterrent Opioids - Evaluation and Labeling: Guidance for Industry [Internet]. 2015. https://www.fda.gov/media/84819/download [cited 2021 Feb 2].
5. Brown JR, Gy Oh, Wang Y, Slavova S, Delcher C, Dasgupta N, et al. Variation in abuse-deterrent formulation opioid prescribing in California, Florida, and Kentucky in 2018. J Rural Health. 2020;37:23–8.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献